Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter? in the upadacitinib ph3 t
Tweet Content
Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter?
in the upadacitinib ph3 trials, high disease activity pts had more:
serious infections
HZ
MACE
VTE
Active RA is a massive contributor to many AEs in JAKi pts
#ACR24 ABST1393 @RheumNow https://t.co/DlFf9Sfbja
Show on Archive Page
On
Display in Search Results
On
PDQ
Off